"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3"

drug protocol number
I6T-MC-AMAP
drug sponsor
Eli Lilly
drug study
Mirikizumab
drug trial site
King Fahad Specialist Hospital (Dammam)
drug status
Completed
drug phase